Abrégé

The present invention relates to an alphavirus RNA replicase coding sequence, an optimized self-amplifying nucleic acid molecule, a pharmaceutical composition, and a use. The optimized self-amplifying nucleic acid molecule is a self-amplifying nucleic acid molecule comprising the alphavirus RNA replicase coding sequence, a tissue-specific self-amplifying nucleic acid molecule, or an improved self-amplifying mRNA comprising a mutated replicase; and the mutated replicase comprises a mutated macro domain. The present invention further relates to a preparation method for the self-amplifying nucleic acid molecule.

Classes IPC  ?

• C12N 15/54 - Transférases (2)
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided herein is a lipid compound that can be used in combination with other lipid components such as a neutral lipid, cholesterol, and a polymer-bound lipid to form a lipid nanoparticle for the delivery of a therapeutic agent (e.g. a nucleic acid molecule), thereby achieving therapeutic or preventive purposes, including vaccination. Further provided herein is a lipid nanoparticle composition containing the lipid compound.

Classes IPC  ?

• C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
• A61K 9/51 - Nanocapsules
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments

Abrégé

A pharmaceutical combination where a checkpoint inhibitor is combined with a recombinant oncolytic virus and the use of said combination for the treatment of cancer.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 35/768 - Virus oncolytiques non prévus dans les groupes
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Compositions and methods are provided for eliciting an immune response in a subject, by (a) administering to a subject a first vaccine, wherein the first vaccine includes a macromolecule or an oncolytic virus capable of inducing an immune response in a subject, and (b) administering a second vaccine, wherein the second vaccine includes an oncolytic virus. Within preferred embodiments of the invention the immune response is used to treat a patient having cancer.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/12 - Antigènes viraux
• A61K 39/02 - Antigènes bactériens
• C12N 15/869 - Vecteurs herpèsviraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux

Abrégé

Compositions and methods are provided for eliciting an immune response in a subject, by (a) administering to a subject a first vaccine, wherein the first vaccine includes a macromolecule or an oncolytic virus capable of inducing an immune response in a subject, and (b) administering a second vaccine, wherein the second vaccine includes an oncolytic virus. Within preferred embodiments, the immune response is used to treat a patient having cancer.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/12 - Antigènes viraux
• A61K 39/02 - Antigènes bactériens
• C12N 15/869 - Vecteurs herpèsviraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux

Abrégé

A nucleic acid molecule, kit and method for detecting a monkey pox virus. The nucleic acid molecule comprises primer molecules having nucleic acid sequences as shown in SEQ ID NO: 5-6 and a probe molecule optionally having a nucleic acid sequence as shown in SEQ ID NO: 7.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12R 1/93 - Virus des animaux

Abrégé

Provided in the present application is a method for preparing a nucleic acid-encapsulation body complex, comprising introducing a nucleic acid into an empty encapsulation body by means of a mode selected from microfluidic mixing and oscillation mixing, so as to obtain a nucleic acid-encapsulation body complex capable of being directly administrated to subjects. Also provided in the present application is a device for preparing a nucleic acid-encapsulation body complex, comprising: a micro-fluidic chip, more than one first feeding containers, more than one second feeding containers and a collection container. Further provided in the present application is a method for preparing a nucleic acid-encapsulation body complex, comprising: in a microfluidic mixing mode, encapsulating a nucleic acid with an encapsulant capable of being self-assembled into an encapsulation body capable of encapsulating the nucleic acid, so as to obtain the nucleic acid-encapsulation body complex capable of being directly administrated to subjects.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• B01F 33/301 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux

Abrégé

A messenger ribonucleic acid (mRNA) molecule, comprising: an expression cassette 1 containing a coding sequence of RNA replicase, and an expression cassette 2 containing a coding sequence of an antigen. Further provided are a mRNA vaccine, which is obtained by encapsulating the mRNA molecule into lipid nanoparticles (LNPs); a DNA molecule, which can be transcribed into the mRNA molecule; and the use of the mRNA molecule in preparing a mRNA vaccine capable of eliciting an anti-HER2 immune response. Further provided is a method for preparing the mRNA molecule, comprising: (1) on the basis of the DNA sequence of the genome of a virus, replacing in a coding sequence of a structural polyprotein the moiety following the promoter of the structural polyprotein with the coding sequence of the antigen; (2) adding a promoter site of RNA polymerase to the 5'-end of 5'-UTR; (3) adding poly-A to the 3'-end of 3'-UTR; and (4) transcribing into a mRNA molecule the DNA molecule constructed by steps (1)-(3).

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
• C12N 15/12 - Gènes codant pour des protéines animales
• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

Immunogenic proteins are provided which have been derived from a strain of HPV which causes or is associated with causing cancer, which are mutated so that they do not cause increased cell proliferation. Within various embodiments of the invention the immunogenic protein is derived (e.g., mutated) from an HPV strain such as HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68. Also provided are compositions (e.g., mRNA compositions) encoding such immunogenic proteins, as well as method for treating and preventing HPV infections.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C07K 19/00 - Peptides hybrides
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

Immunogenic proteins are provided which have been derived from a strain of HPV which causes or is associated with causing cancer, which are mutated so that they do not cause increased cell proliferation. In various embodiments, the immunogenic protein is derived (e.g., mutated) from an HPV strain such as HPV 16, 18, 31, 33,35, 39, 45, 51, 52, 56, 58, 59, 66 or 68. Also provided are compositions (e.g., mRNA compositions) encoding such immunogenic proteins, as well as method for treating and preventing HPV infections.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
• A61P 35/00 - Agents anticancéreux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The present invention relates to an anti-poxvirus vaccine, which comprises an mRNA molecule encoding the following proteins and/or fusion proteins: (a) more than one monkey poxvirus protein selected from the following: an A35R protein, an M1R protein, a B6R protein, and an A29L protein, and/or (b) a fusion protein formed by fusing two or more monkey poxvirus proteins or parts of proteins selected from the following: an A35R protein, an M1R protein, a B6R protein, and an A29L protein. The present invention also relates to a kit for preparing the anti-poxvirus vaccine, which comprises: (i) a DNA molecule encoding the described protein and/or fusion protein, and optionally (ii) a reagent for transcribing the DNA molecule of (i) into an mRNA molecule. The present invention also relates to a DNA molecule or mRNA molecule encoding the described protein and fusion protein.

Classes IPC  ?

• A61K 39/275 - Poxviridae, p. ex. Avipoxvirus
• A61K 9/51 - Nanocapsules
• C12N 15/39 - Poxviridae, p. ex. virus de la vaccine, virus de la variole
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

An HSV vector with ICP27 under control of CXCR4 promoter and miRNA-223/125b and ICP34.5 under control of miRNA-124/143, and deletion of one RL and one RS region of the viral genome. Within optional embodiments the mutation is a deletion containing the second copy of the ICP34.5 gene. The HSV vector also incorporates a virus-expressed cytokine cassette encoding IL-12, IL-15/1 L-15RA under the control of CMV promoter.

Classes IPC  ?

• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 35/763 - Virus de l’herpès
• A61P 35/00 - Agents anticancéreux
• C12R 1/93 - Virus des animaux

Abrégé

An HSV vector with ICP27 under control of CXCR4 promoter and miRNA-223/125b and ICP34.5 under control of miRNA-124/143, and deletion of one RL and one RS region of the viral genome. Within optional embodiments the mutation is a deletion containing the second copy of the ICP34.5 gene. The HSV vector also incorporates a virus-expressed cytokine cassette encoding IL-12, IL-15/IL-15RA under the control of CMV promoter.

Classes IPC  ?

• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 35/763 - Virus de l’herpès
• A61P 35/00 - Agents anticancéreux
• C12R 1/93 - Virus des animaux

Abrégé

Recombinant multivalent proteins are provided having two or more angiotensin-converting enzyme 2 (ACE2) fragments and a human immunoglobin Fc domain, wherein the ACE2 fragments are capable of binding to a coronavirus. Within one embodiment the human immunoglobin Fc domain has an N-terminal flexible hinge region which is joined to the C-terminal ends of a first and a second of the two or more ACE2 fragments. Also provided are expression vectors and host cells for producing the recombinant multivalent proteins, as well as pharmaceutical compositions comprising recombinant multivalent proteins, and methods of using the same (e.g., for the treatment and/or prevention of coronavirus infections).

Classes IPC  ?

• C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

Recombinant multivalent proteins are provided having two or more angiotensin-converting enzyme 2 (ACE2) fragments and a human immunoglobin Fc domain, wherein the ACE2 fragments are capable of binding to a coronavirus. Within one embodiment the human immunoglobin Fc domain has an N-terminal flexible hinge region which isjoined to the C-terminal ends of a first and a second of the two or more ACE2 fragments. Also provided are expression vectors and host cells for producing the recombinant multivalent proteins, as well as pharmaceutical compositions comprising recombinant multivalent proteins, and methods of using the same (e.g., for the treatment and/or prevention of coronavirus infections).

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• A61P 31/14 - Antiviraux pour le traitement des virus ARN